Home dialysis : conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Copyright © 2023 International Society of Nephrology. Published by Elsevier Inc. All rights reserved..
Home dialysis modalities (home hemodialysis [HD] and peritoneal dialysis [PD]) are associated with greater patient autonomy and treatment satisfaction compared with in-center modalities, yet the level of home-dialysis use worldwide is low. Reasons for limited utilization are context-dependent, informed by local resources, dialysis costs, access to healthcare, health system policies, provider bias or preferences, cultural beliefs, individual lifestyle concerns, potential care-partner time, and financial burdens. In May 2021, KDIGO (Kidney Disease: Improving Global Outcomes) convened a controversies conference on home dialysis, focusing on how modality choice and distribution are determined and strategies to expand home-dialysis use. Participants recognized that expanding use of home dialysis within a given health system requires alignment of policy, fiscal resources, organizational structure, provider incentives, and accountability. Clinical outcomes across all dialysis modalities are largely similar, but for specific clinical measures, one modality may have advantages over another. Therefore, choice among available modalities is preference-sensitive, with consideration of quality of life, life goals, clinical characteristics, family or care-partner support, and living environment. Ideally, individuals, their care-partners, and their healthcare teams will employ shared decision-making in assessing initial and subsequent kidney failure treatment options. To meet this goal, iterative, high-quality education and support for healthcare professionals, patients, and care-partners are priorities. Everyone who faces dialysis should have access to home therapy. Facilitating universal access to home dialysis and expanding utilization requires alignment of policy considerations and resources at the dialysis-center level, with clear leadership from informed and motivated clinical teams.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
|---|---|
| Enthalten in: |
Kidney international - 103(2023), 5 vom: 01. Mai, Seite 842-858 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Perl, Jeffrey [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dialysis modality |
|---|
| Anmerkungen: |
Date Completed 25.04.2023 Date Revised 29.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.kint.2023.01.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352418346 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352418346 | ||
| 003 | DE-627 | ||
| 005 | 20231226053701.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.kint.2023.01.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352418346 | ||
| 035 | |a (NLM)36731611 | ||
| 035 | |a (PII)S0085-2538(23)00051-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Perl, Jeffrey |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Home dialysis |b conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2023 | ||
| 500 | |a Date Revised 29.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 International Society of Nephrology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Home dialysis modalities (home hemodialysis [HD] and peritoneal dialysis [PD]) are associated with greater patient autonomy and treatment satisfaction compared with in-center modalities, yet the level of home-dialysis use worldwide is low. Reasons for limited utilization are context-dependent, informed by local resources, dialysis costs, access to healthcare, health system policies, provider bias or preferences, cultural beliefs, individual lifestyle concerns, potential care-partner time, and financial burdens. In May 2021, KDIGO (Kidney Disease: Improving Global Outcomes) convened a controversies conference on home dialysis, focusing on how modality choice and distribution are determined and strategies to expand home-dialysis use. Participants recognized that expanding use of home dialysis within a given health system requires alignment of policy, fiscal resources, organizational structure, provider incentives, and accountability. Clinical outcomes across all dialysis modalities are largely similar, but for specific clinical measures, one modality may have advantages over another. Therefore, choice among available modalities is preference-sensitive, with consideration of quality of life, life goals, clinical characteristics, family or care-partner support, and living environment. Ideally, individuals, their care-partners, and their healthcare teams will employ shared decision-making in assessing initial and subsequent kidney failure treatment options. To meet this goal, iterative, high-quality education and support for healthcare professionals, patients, and care-partners are priorities. Everyone who faces dialysis should have access to home therapy. Facilitating universal access to home dialysis and expanding utilization requires alignment of policy considerations and resources at the dialysis-center level, with clear leadership from informed and motivated clinical teams | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a dialysis modality | |
| 650 | 4 | |a healthcare policy | |
| 650 | 4 | |a hemodialysis | |
| 650 | 4 | |a home dialysis | |
| 650 | 4 | |a peritoneal dialysis | |
| 650 | 4 | |a quality of life | |
| 700 | 1 | |a Brown, Edwina A |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Christopher T |e verfasserin |4 aut | |
| 700 | 1 | |a Couchoud, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Simon J |e verfasserin |4 aut | |
| 700 | 1 | |a Kazancioğlu, Rümeyza |e verfasserin |4 aut | |
| 700 | 1 | |a Klarenbach, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Liew, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Weiner, Daniel E |e verfasserin |4 aut | |
| 700 | 1 | |a Cheung, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Jadoul, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Winkelmayer, Wolfgang C |e verfasserin |4 aut | |
| 700 | 1 | |a Wilkie, Martin E |e verfasserin |4 aut | |
| 700 | 0 | |a for Conference Participants |e verfasserin |4 aut | |
| 700 | 1 | |a Abrahams, Alferso C |e investigator |4 oth | |
| 700 | 1 | |a Anumudu, Samaya J |e investigator |4 oth | |
| 700 | 1 | |a Bargman, Joanne M |e investigator |4 oth | |
| 700 | 1 | |a Moore, Geraldine Biddle |e investigator |4 oth | |
| 700 | 1 | |a Blake, Peter G |e investigator |4 oth | |
| 700 | 1 | |a Borman, Natalie |e investigator |4 oth | |
| 700 | 1 | |a Bowes, Elaine |e investigator |4 oth | |
| 700 | 1 | |a Burton, James O |e investigator |4 oth | |
| 700 | 1 | |a Caillette-Beaudoin, Agnes |e investigator |4 oth | |
| 700 | 1 | |a Cho, Yeoungjee |e investigator |4 oth | |
| 700 | 1 | |a Cullis, Brett |e investigator |4 oth | |
| 700 | 1 | |a Einbinder, Yael |e investigator |4 oth | |
| 700 | 1 | |a El Shamy, Osama |e investigator |4 oth | |
| 700 | 1 | |a Erickson, Kevin F |e investigator |4 oth | |
| 700 | 1 | |a Figueiredo, Ana E |e investigator |4 oth | |
| 700 | 1 | |a Finkelstein, Fred |e investigator |4 oth | |
| 700 | 1 | |a Fluck, Richard |e investigator |4 oth | |
| 700 | 1 | |a Flythe, Jennifer E |e investigator |4 oth | |
| 700 | 1 | |a Fotheringham, James |e investigator |4 oth | |
| 700 | 1 | |a Fukagawa, Masafumi |e investigator |4 oth | |
| 700 | 1 | |a Goffin, Eric |e investigator |4 oth | |
| 700 | 1 | |a Golper, Thomas A |e investigator |4 oth | |
| 700 | 1 | |a Gómez, Rafael |e investigator |4 oth | |
| 700 | 1 | |a Jha, Vivekanand |e investigator |4 oth | |
| 700 | 1 | |a Johnson, David W |e investigator |4 oth | |
| 700 | 1 | |a Kanjanabuch, Talerngsak |e investigator |4 oth | |
| 700 | 1 | |a Kim, Yong-Lim |e investigator |4 oth | |
| 700 | 1 | |a Lambie, Mark |e investigator |4 oth | |
| 700 | 1 | |a Lerma, Edgar V |e investigator |4 oth | |
| 700 | 1 | |a Lockridge, Robert S |e investigator |4 oth | |
| 700 | 1 | |a Loud, Fiona |e investigator |4 oth | |
| 700 | 1 | |a Masakane, Ikuto |e investigator |4 oth | |
| 700 | 1 | |a Matthews, Nicola |e investigator |4 oth | |
| 700 | 1 | |a McKane, Will |e investigator |4 oth | |
| 700 | 1 | |a Mendelssohn, David C |e investigator |4 oth | |
| 700 | 1 | |a Mettang, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Mitra, Sandip |e investigator |4 oth | |
| 700 | 1 | |a Moraes, Thyago Proença de |e investigator |4 oth | |
| 700 | 1 | |a Morton, Rachael |e investigator |4 oth | |
| 700 | 1 | |a Mushahar, Lily |e investigator |4 oth | |
| 700 | 1 | |a Nadeau-Fredette, Annie-Claire |e investigator |4 oth | |
| 700 | 1 | |a Nayak, K S |e investigator |4 oth | |
| 700 | 1 | |a Neumann, Joanna L |e investigator |4 oth | |
| 700 | 1 | |a Ngaruiya, Grace |e investigator |4 oth | |
| 700 | 1 | |a Okpechi, Ikechi |e investigator |4 oth | |
| 700 | 1 | |a Quinn, Robert R |e investigator |4 oth | |
| 700 | 1 | |a Rangaswami, Janani |e investigator |4 oth | |
| 700 | 1 | |a Reddy, Yuvaram N V |e investigator |4 oth | |
| 700 | 1 | |a Schiller, Brigitte |e investigator |4 oth | |
| 700 | 1 | |a Shen, Jenny I |e investigator |4 oth | |
| 700 | 1 | |a Shroff, Rukshana |e investigator |4 oth | |
| 700 | 1 | |a Slon Roblero, Maria Fernanda |e investigator |4 oth | |
| 700 | 1 | |a Solá, Laura |e investigator |4 oth | |
| 700 | 1 | |a Søndergaard, Henning |e investigator |4 oth | |
| 700 | 1 | |a Teitelbaum, Isaac |e investigator |4 oth | |
| 700 | 1 | |a Tennankore, Karthik |e investigator |4 oth | |
| 700 | 1 | |a Van Ommeslaeghe, Floris |e investigator |4 oth | |
| 700 | 1 | |a Walker, Rachael C |e investigator |4 oth | |
| 700 | 1 | |a Walker, Robert J |e investigator |4 oth | |
| 700 | 1 | |a Wang, Angela Yee-Moon |e investigator |4 oth | |
| 700 | 1 | |a Warady, Bradley A |e investigator |4 oth | |
| 700 | 1 | |a Watnick, Suzanne |e investigator |4 oth | |
| 700 | 1 | |a Weinhandl, Eric D |e investigator |4 oth | |
| 700 | 1 | |a Wilkie, Caroline M |e investigator |4 oth | |
| 700 | 1 | |a Williams, Jennifer |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney international |d 1972 |g 103(2023), 5 vom: 01. Mai, Seite 842-858 |w (DE-627)NLM000007188 |x 1523-1755 |7 nnns |
| 773 | 1 | 8 | |g volume:103 |g year:2023 |g number:5 |g day:01 |g month:05 |g pages:842-858 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.kint.2023.01.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 103 |j 2023 |e 5 |b 01 |c 05 |h 842-858 | ||